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        Despite the development of more potent anti-
malarial drugs, there has been little progress in 
identifying interventions that improve the out-
come of cerebral malaria (CM) (  1, 2  ). This may 
be attributable, at least partly, to the observation 
that severe malaria syndromes such as CM ap-
pear to be primarily mediated by host responses 
to infection rather than by the parasite directly. 
  Experimental infection of inbred and con-
genic mice with   Plasmodium berghei   ANKA (PbA) 
provides a well-established model to identify 
host genetic determinants that regulate both 
protective immunity and infection-associated 
immunopathology, including the develop-
ment of CM. Similar to   P. falciparum   infection 
in humans, mice susceptible to PbA (e.g., 
C57BL/6 mice) develop symptoms of severe 
malaria and CM, including cytokine-associated 
encephalopathy, acidosis, coagulopathy, shock, 
and pulmonary edema, culminating in a fatal 
outcome ( 3  –  5  ). Conversely, A/J mice, although 
equally susceptible to PbA infection, are more 
resistant to the associated CM syndrome (  6  –  7  ). 
  Excessive or dysregulated infl  ammatory re-
sponses to malaria, including high levels of 
TNF/lymphotoxin-     or inadequate production 
of regulatory (antiinfl  ammatory) cytokines such 
as TGF-     and IL-10, are associated with the 
development of CM in both human infections 
and rodent models of disease (  4, 8  –  12  ). High 
levels of infl  ammatory cytokines are associated 
with endothelial cell activation and increased 
expression of adhesion molecules that contribute 
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  Experimental infection of mice with   Plasmodium berghei   ANKA (PbA) provides a powerful 
model to defi  ne genetic determinants that regulate the development of cerebral malaria 
(CM). Based on the hypothesis that excessive activation of the complement system may 
confer susceptibility to CM, we investigated the role of C5/C5a in the development of CM. 
We show a spectrum of susceptibility to PbA in a panel of inbred mice; all CM-susceptible 
mice examined were found to be   C5   suffi  cient, whereas all   C5  -defi  cient strains were resis-
tant to CM. Transfer of the   C5  -defective allele from an A/J (CM resistant) onto a C57BL/6 
(CM-susceptible) genetic background in a congenic strain conferred increased resistance to 
CM; conversely, transfer of the   C5  -suffi  cient allele from the C57BL/6 onto the A/J back-
ground recapitulated the CM-susceptible phenotype. The role of   C5   was further explored in 
B10.D2 mice, which are identical for all loci other than   C5  .   C5  -defi  cient B10.D2 mice were 
protected from CM, whereas   C5  -suffi  cient B10.D2 mice were susceptible. Antibody block-
ade of C5a or C5a receptor (C5aR) rescued susceptible mice from CM. In vitro studies 
showed that C5a-potentiated cytokine secretion induced by the malaria product   P. falci-
parum   glycosylphosphatidylinositol and C5aR blockade abrogated these amplifi  ed responses. 
These data provide evidence implicating   C5/  C5a in the pathogenesis of CM. 1134 DISRUPTION OF   C5   CONFERS RESISTANCE TO CEREBRAL MALARIA | Patel et al.
survival during the acute phase of infection (  6, 7, 25  –  27  ). 
To more completely defi  ne the phenotypic expression of diff  er-
ential susceptibility in this experimental model, we simulta-
neously challenged a panel of inbred mice under carefully 
controlled experimental conditions with a uniform inoculum 
of PbA and examined parasitemia, the development of experi-
mental CM, and survival over a course of infection (  Table I   
and   Fig. 1 A  ).   We observed diff  erences in survival between 
A/J and C57BL/6 mice (A/J vs. C57BL/6: P = 0.002 and 
      2   = 9.879 using a log-rank test for survival;   Fig. 1 A  ). However, 
in this analysis a broader spectrum of susceptibility was ob-
served than previously reported (  6, 7, 25  –  27  ). This phenotypic 
expression ranged from highly susceptible to highly resistant 
to experimental CM (  Table I   and   Fig. 1 A  ). Compared with 
CM-susceptible C57BL/6 mice, highly susceptible mice such 
as 129sv/J and 129P3/J mice had an earlier onset of neuro-
logical symptoms and succumbed signifi  cantly sooner to CM 
(as confi  rmed by histopathology;   Fig. 1 C  ) during the course 
of infection (P = 0.001 and       2   = 11.317 using a log-rank 
test). In contrast, AKR/J mice were highly resistant, with 
signifi  cantly improved survival compared with other strains 
(P = 0.00001 and       2   = 13.568 using a log-rank test;   Fig. 1 C  ). 
To examine whether parasite burden contributed to these 
diff  erent phenotypes, we examined the parasitemia in these 
inbred lines. No signifi  cant diff  erence in parasitemia was 
observed between susceptible, resistant, and highly resis-
tant mice throughout the course of infection (  Fig. 1 B   and 
Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20072248/DC1). In contrast, highly susceptible mice, 
such as 129sv/J mice, developed signifi  cantly higher parasite 
burdens earlier in the course of infection, as indicated by day 
6 peripheral parasitemias (P = 0.006 using a Kruskal-Wallis 
test;   Fig. 1 B  ). 
    C5   suffi  ciency is associated with susceptibility to CM 
  To test the hypothesis that excessive C5a generation may 
confer susceptibility to CM, we determined the   C5   status in 
the panel of susceptible and resistant mice we had pheno-
typed, as well as those reported in the literature (  Table I  ) (  26  –  28  ). 
C57BL/6, 129sv/J, and 129P3/J strains were shown to be 
susceptible to PbA-induced CM, and each of these strains 
is   C5   suffi   cient (wild-type sequence for   C5  ). A/J, DBA/2J, 
and AKR/J mice are   C5   defi  cient (i.e., they possess a known 
frame-shift mutation in the   C5   gene and do not express func-
tional C5) and were signifi  cantly more resistant to PbA-
induced CM. A similar association of CM with   C5   suffi   ciency 
was established by determining the   C5   status of other inbred 
mouse strains reported in the literature as susceptible or resis-
tant to PbA. In each case, inbred mice reported to be suscep-
tible to CM were found to be   C5   suffi   cient. Conversely, all 
  C5  -defi  cient mice analyzed in this study and those reported in 
the literature were found to be resistant to CM. However there 
were two notable exceptions to this association. C3H/HeN 
mice are reported to be   C5   suffi   cient but resistant to CM (  28  ). 
We genotyped and phenotyped this strain together with ap-
propriate controls and determined that it contained a wild-type 
to the sequestration of parasitized erythrocytes and leukocytes 
in the cerebral vascular bed and the resultant CM syndrome 
(  10, 13  –  15  ). Although it is well established that host response 
contributes to the development of CM, the underlying genetic 
determinants of susceptibility are poorly characterized (  10  ). 
A detailed understanding of the host genetic factors that con-
tribute to susceptibility or resistance to CM may facilitate the 
identifi  cation of novel interventions to modulate host response 
and improve the outcome of CM (  2, 15  ). 
  The complement system is an essential component of 
the innate immune response to several infectious agents (  16  ). 
The complement cascade can be activated by four diff  erent 
pathways, three of which converge at the level of the C3 
component, leading to the cleavage of C3 and C5 to their 
activated forms, C3a and C5a, as well as the formation of 
the terminal membrane attack complex (  17, 18  ). A recently 
described pathway results in the generation of C5a in the 
absence of C3 (  19  ). 
  A growing body of evidence has implicated excessive acti-
vation of the complement system, especially formation of the 
potent proinfl  ammatory anaphylatoxin C5a in mediating del-
eterious host responses to bacterial infections and contributing 
to the development of sepsis, adverse outcomes, and death 
(  16, 18, 20  ). Blockade of C5a activity or C5aR with antibod-
ies or C5aR antagonists in animal models of sepsis prevents 
multiorgan injury and improves survival (  19, 21  –  24  ). Genera-
tion of C5a is normally tightly regulated, and under controlled 
conditions, local production of C5a can enhance eff  ector 
function of macrophages and neutrophils and contribute to an 
eff  ective innate response to infection. However, detectable 
systemic C5a suggests a loss of regulation of complement 
activation. Elevated C5a levels are associated with several 
deleterious eff  ects on host innate defense, including defective 
phagocyte and endothelial cell function, robust chemokine and 
cytokine secretion, and lymphoid apoptosis (  16, 18, 20  ). 
  Similar to sepsis, CM is believed to be the result, at least 
partly, of a dysregulated infl  ammatory response to infection. 
However, the roles of   C5   and C5a in the pathogenesis of CM 
have not been studied. We hypothesized that excessive gener-
ation of C5a in response to infection confers susceptibility to 
CM and investigated the role of C5a in the development of 
CM in vivo. Using a panel of inbred and congenic mice, we 
demonstrate a spectrum of diff  erential susceptibility to CM 
that is associated with the presence or absence of   C5   and the 
generation of C5a, as well as the engagement of C5aR. These 
data provide direct evidence indicating that C5a plays a role in 
the pathogenesis of CM in the PbA model. 
    RESULTS   
  Differential susceptibility of inbred mice to PbA-induced 
experimental CM 
  Previous studies have established that inbred strains of mice 
such as C57BL/6 are susceptible to PbA infection and de-
velop symptoms of experimental CM and rapidly succumb 
to infection. In contrast, other inbred mice, such as DBA/2 
or A/J mice, are more resistant to CM and display enhanced JEM VOL. 205, May 12, 2008 
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sequence for   C5   and was sensitive to PbA-induced CM, with 
a survival course similar to CM-susceptible C57BL/6 mice 
(  Table I   and   Fig. 2  ).   BALB/c mice are also reported to be 
resistant to CM and   C5   suffi   cient (  8, 27, 29  ). Because sev-
eral diff  erent lines of BALB/c mice are in current use and be-
cause C5   “  suffi   ciency  ”   in the literature often meant only that 
the   C5   gene did not contain the single A/J frame-shift muta-
tion (as detected by PCR), we phenotyped the line in use in 
our laboratory and investigated this line for the presence of 
  C5   suffi   ciency by sequencing the entire   C5   gene to exclude 
any other point mutations, confi  rming gene transcription us-
ing RT-PCR, and by measuring C5a production over the 
course of PbA infection by ELISA. BALB/c mice were found 
to be resistant to the development of CM, with signifi  cantly 
higher survival than C57BL/6 mice (  Fig. 3 A  ).   Sequence 
analysis showed that the   C5   gene from BALB/c mice con-
tained no mutations in the open reading frame and therefore 
would have been predicted, by our hypothesis, to be suscep-
tible to PbA-induced CM. To explain this apparent discrep-
ancy, serum C5a levels in BALB/c and C57BL/6 mice over 
the course of an infection were analyzed. CM-susceptible 
C57BL/6 mice were shown to have signifi  cantly higher 
levels of C5a in the peripheral blood than BALB/c mice dur-
ing infection, particularly at early time points (  Fig. 3 B  ). 
These observations were also supported by RT-PCR analysis 
demonstrating that BALB/c mice have levels of C5 that are 
signifi  cantly lower than susceptible C57BL/6 mice and are 
    Table I.        PbA-induced experimental CM is associated with the 
presence of the   C5   gene 
Strain   C5   status CM phenotype    a   
  C57BL/6   Suffi  cient    Susceptible 
  C57BL/10   Suffi  cient   Susceptible 
  CBA/Ca   Suffi  cient   Susceptible 
  DBA/1   Suffi  cient   Susceptible 
  SJL/J   Suffi  cient   Susceptible 
  129sv/J   Suffi  cient   Highly susceptible 
  129P3/J   Suffi  cient   Highly susceptible 
  C3H/HeN   Suffi  cient   Susceptible 
  B10.D2/nSnJ   Suffi  cient   Susceptible 
  B10.D2/oSnJ   Defi  cient   Resistant 
  A/J   Defi  cient   Resistant 
  DBA/2   Defi  cient   Resistant 
  AKR/J   Defi  cient   Highly resistant 
  BALB/c   Suffi  cient   Highly resistant 
  a  CM phenotype describes mice that were judged as developing CM if they displayed 
neurological symptoms including mono-, hemi-, para-, or tetraplegia, movement 
disorder, ataxia, hunching, convulsions, and coma, and succumbed to infection by 
day 12 after inoculation (references   6, 7  ). Susceptible strains developed neurological 
symptoms within 6  –  10 d after inoculation. Highly susceptible mice showed both a 
signifi  cantly higher parasite density and an early onset of neurological symptoms 
and death than susceptible mouse strains. Resistant strains displayed a signifi  cantly 
delayed onset of neurological symptoms and improved survival compared with 
susceptible groups. Highly resistant strains did not develop neurological symptoms 
and displayed enhanced survival compared with resistant strains. Strains analyzed 
in this study are bolded. Other strains (italicized) were derived as previously 
described  (references   26 – 28 ).
similar to C5-null A/J mice (BALB/c vs. C57BL/6 mean [SD] 
day 1 C5 mRNA copy number = 427.1 [471] vs. 4,132 [961], 
P = 0.002; BALB/c vs. A/J mean [SD] day 1 C5 mRNA copy 
number = 427.1 [471] vs. 691.6 [480], P = 0.498). These data 
indicate that susceptibility to PbA-induced CM is associated 
with   C5   suffi   ciency and support a role for the generation of 
C5a early during the course of infection as a putative media-
tor of CM in susceptible animals. 
  Congenic mice confi  rm a role for   C5   in susceptibility to CM 
  The phenotypic diff  erences to PbA infection between the 
inbred mouse lines observed in   Table I   could be either the 
direct result of   C5   suffi   ciency/defi  ciency or secondary to other 
genetic factors acting alone or in combination with   C5  . There-
fore, we further explored the hypothesis that C5a contrib-
utes to the pathogenesis of CM by examining the phenotype 
in recombinant congenic mice and in closely related mouse 
lines that diff  er in the presence or absence of   C5  . Recombi-
nant congenic mice were derived from systematic inbreed-
ing of a double backcross between   C5  -defi  cient A/J mice and 
CM-susceptible,   C5  -suffi   cient C57BL/6 mice (  30  ). In this 
system, each congenic strain contains a fi  xed set of congenic 
segments (12.5% of DNA from the donor parent) placed 
on the genetic background of the recipient parent (87.5% of 
DNA). Thus, AcB55 recombinant congenic mice contain 
12.5% of C57BL/6 genetic material, including a functional 
  C5   gene, on a predominantly A/J genetic background (  30  ); 
conversely, BcA76 recombinant congenic mice are composed 
of 12.5% A/J genetic material (including the mutant   C5   
gene) on a C57BL/6 background. Experimental challenge 
of these recombinant congenic mice with PbA showed 
that transfer of the   C5  -suffi   cient allele onto an A/J back-
ground, as in AcB55 mice, accelerated the development of 
CM and fatal outcomes compared with the parental A/J 
(  C5  -defi  cient) mice (A/J vs. AcB55: P   <   0.05 and       2   = 4 
using a log-rank test). In contrast, BcA76 mice that carry 
the A/J   C5   defi  ciency allele had reduced incidence of CM 
and improved survival compared with the parental C57BL/6 
mice (C57BL/6 vs. BcA76: P   <   0.05 and       2   = 4.038 using 
a log-rank test;   Fig. 4  ).   We found no diff  erence in parasite 
burden between congenic AcB55 and BcA76 mice (unpub-
lished data). 
  In addition to the recombinant congenic mice, we also 
examined PbA-induced CM susceptibility in congenic B10.
D2/nSnJ and B10.D2/oSnJ mice, which are genetically iden-
tical strains except that the B10.D2/nSnJ strain is   C5   suffi   -
cient, whereas B10.D2/oSnJ mice contain the mutant allele 
of the   C5   gene (with both on a C57BL/10 background). 
B10.D2/nSnJ mice were found to be susceptible to PbA-
  induced CM and rapidly succumbed to infection, whereas B10.
D2/oSnJ mice displayed signifi  cantly improved survival (P   <   
0.0001 and       2   = 12.274 using a log-rank test;   Fig. 5 A  ).   C5a 
levels were examined over the course of infection, and B10.
D2/nSnJ mice displayed signifi  cantly higher levels of cir-
culating C5a as early as day 1 after infection (  Fig. 5 B  ). 
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    Figure 1.         Differential susceptibility to PbA-induced experimental CM.   The phenotypes of inbred mice strains infected with PbA range from highly 
susceptible (early onset of cerebral symptoms and high parasitemia) to highly resistant (very little mortality caused by CM). (A) 129sv/J mice were highly 
susceptible and died signifi  cantly earlier than C57BL/6 mice (C57BL/6 vs. 129sv/J: P = 0.001 and     2   = 9.879 using a Mantel-Cox log-rank test). A/J mice 
survived signifi  cantly longer than C57BL/6 mice (A/J vs. C57BL/6: P = 0.001 and     2   = 9.879 using a Mantel-Cox log-rank test). AKR/J mice were highly 
resistant and had signifi  cantly improved survival rates compared with all other strains (A/J vs. AKR/J: P = 0.00001 and     2   = 13.568 using a Mantel-Cox 
log-rank test). The fi  gure is representative of two independent experiments (  n   = 10 mice/group/experiment). 100% of 129sv/J and C57BL/6 mice developed JEM VOL. 205, May 12, 2008 
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rank test;   Fig. 7  ).   Similar results were obtained using anti-C5a 
serum (P = 0.0019 using a log-rank test; unpublished data). 
These data provide the fi  rst direct evidence that the blockade 
of complement activation improves outcome in experimental 
CM and demonstrate that C5a  –  C5aR interactions play a central 
role in initiating and/or amplifying CM. 
    DISCUSSION   
  This study provides the fi  rst evidence implicating excessive 
activation of the complement system, in particular C5a, in 
mediating experimental CM. We demonstrate a spectrum of 
diff  erential susceptibility to PbA-induced CM associated with 
the presence or absence of   C5   (  Fig. 1 and Fig. 2  ). A role for 
  C5   was confi  rmed by reciprocal transfer of   C5  -defective 
or -suffi   cient alleles in recombinant congenic mice and by para-
site challenge of genetically identical mice that diff  er only at 
the   C5   locus (  Fig. 4 and Fig. 5  ). In vitro experiments suggest 
that the mechanism by which C5a contributes to CM in-
cludes the potentiation of host infl  ammatory responses to 
malaria products such as   PfGPI   (  Fig. 6  ). Additionally, our 
fi  ndings that disruption of C5a  –  C5aR interactions blocks 
augmented infl  ammatory responses in vitro and leads to pro-
tection from CM in vivo (  Fig. 6 and Fig. 7  ) demonstrate that 
complement activation has a pivotal and causative role in 
mediating or amplifying the CM syndrome. Collectively, 
these data provide direct evidence for a role for C5a in the 
development of CM in the PbA model and suggest a poten-
tial role for excessive complement activation in the patho-
genesis of CM. 
  There are several putative mechanisms by which exces-
sive complement activation might mediate or augment the 
pathophysiologic mechanisms underlying CM. During sep-
sis, activation of the complement system, particularly the 
generation of C5a, has been associated with several deleteri-
ous impacts on host defense, including defective phagocyte 
function and oxidative killing; potentiated macrophage che-
mokine and cytokine secretion in response to TLR ligands 
such as LPS, caspase activation, T cell apoptosis, and associ-
ated immunodefi  ciency; and enhanced secretion of proin-
fl  ammatory mediators and tissue factor from endothelium 
(  17, 19, 21  ). Excessive generation of C5a during severe malaria 
infections may contribute to similar defects in host response. 
C5a has been shown to up-regulate several endothelial cell 
adhesion molecules relevant to parasite sequestration and 
malaria pathogenesis, including intercellular cellular adhe-
sion molecule 1, vascular cellular adhesion molecule 1, and 
P- and E-selectins (  21, 34  –  36  ). Increased expression of ad-
hesion molecules, particularly in the cerebral microvascula-
ture, would be expected to enhance leukocyte and parasitized 
mice, these data further support the contention that an early 
and sustained induction of C5a confers susceptibility to CM. 
  Association of   C5   status with CM susceptibility in con-
genic and recombinant congenic mice support the hypothesis 
that C5 is an important pathological contributor to the host 
response. Furthermore, with confi  rmation in genetically iden-
tical B10.D2 mice that diff  er only at the   C5   locus, we can re-
move the roles of other background genetic eff  ects and state 
more confi  dently that the   C5   gene itself infl  uences overall 
outcome in experimental CM. 
  C5a enhances   P. falciparum   glycosylphosphatidylinositol 
(  Pf  GPI)  –  induced proinfl  ammatory responses in vitro 
  High levels of proinfl  ammatory cytokines are associated with 
CM in humans and in mouse models (  2  –  6  ). The   P. falciparum   
product   Pf  GPI has been shown to induce proinfl  ammatory 
cytokine responses in a Toll-like receptor (TLR) 2  –  dependent 
manner (  31  –  33  ). Because C5a may potentiate infl  ammatory 
cytokine induction to other TLR ligands, such as LPS, and 
because we show that peripheral C5a levels are signifi  cantly 
higher in susceptible mice during malaria infection, we in-
vestigated whether the presence of C5a enhances   Pf  GPI-
induced TNF and IL-6 production in vitro. The exposure of 
human PBMCs to HPLC-purifi  ed   Pf  GPI in vitro induced the 
production of TNF and IL-6. The addition of C5a potenti-
ated   Pf  GPI-induced cytokine production, whereas C5aR 
blockade using anti-C5aR antibody signifi  cantly inhibited TNF 
and IL-6 production (TNF, P = 0.0064; and IL-6, P = 
0.0001 using a two-way analysis of variance interaction eff  ect 
[C5*  Pf  GPI];   Fig. 6, A and B  ).   These data indicate that C5a 
augments   PfGPI  -stimulated TNF and IL-6 production and, 
thus, may play a signifi  cant role in the development of the 
CM syndrome observed in susceptible mice. 
  C5a and C5aR blockade rescues susceptible mice 
from experimental CM 
  The above genetic approaches implicated C5 in the patho-
genesis of CM. C5 cleavage generates two eff  ector pathways, 
the potent anaphylatoxin C5a and C5b, which initiates the 
C5b-9 membrane attack complex. To distinguish the role of 
C5a from the C5b-9 membrane attack complex in PbA in-
fection and to provide direct evidence that C5a is a mediator 
of CM rather than a consequence of infection, we performed 
C5a and C5aR blockade experiments to determine whether 
we could protect susceptible mice from CM. Treatment of 
B10.D2/nSnJ (C5-suffi   cient) mice with anti-C5aR antibod-
ies early in PbA infection (2 h before and 30 h after infection) 
conferred signifi  cant protection from CM compared with 
mice that received control serum (P = 0.0022 using a log-
CM (as described in Materials and methods), compared with 30% of A/J and 0% of AKR/J mice. (B) 129sv/J mice had signifi  cantly higher mean parasitemia 
than other CM-susceptible or -resistant mice on day 6 after infection (P = 0.006 using a Kruskal-Wallis test). Representative data from one of two inde-
pendent experiments (  n   = 5 mice/group/experiment) are shown. Data are presented as means   ±   SD. (C) Histopathological examination of brains from 
susceptible (129sv/J, B10.D2/nSnJ, and C57BL/6) and resistant (AKR/J, B10.D2/oSnJ, and BALB/c) mice, isolated on day 6 after inoculation and formalin 
fi  xed. 5-  μ  M sections were prepared and stained with Giemsa. CM-susceptible mice displayed characteristic histological evidence of CM, including the 
accumulation of mononuclear cells and parasitized erythrocytes in the microvasculature. Bar, 50   μ  M.     
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experimental CM. Collectively, these observations indicate 
that CM is a complex and polygenic process, and that in 
highly susceptible and highly resistant strains other genetic 
factors, in addition to   C5  , contribute to the phenotypes ob-
served. Although the precise genetic determinants regulating the 
control of acute blood-stage parasite replication in   P. berghei   
are unknown, studies have identifi  ed several loci, including 
  Char1  ,   Char2  ,   Char3  , and   Char9  , in the control of peak par-
asitemia in   P. chabaudi    –  infected mice (  47  –  50  ); more recently, 
  Berr1  ,   Berr3  ,   Berr4  , and   cmsc   loci on chromosomes 1, 9, 4, and 
17 (in the H-2 region), respectively, have been associated with 
the genetic control of host response (  26, 51  –  52  ). 
erythrocyte adherence to endothelium, contributing to the 
release of toxic mediators, disruption of microcirculatory fl  ow 
and regional metabolism, and endothelial cell activation and 
injury that characterize CM (  37  –  39  ). Similar to sepsis, dys-
regulated infl  ammatory responses to microbial products have 
also been implicated as key factors in the pathogenesis of 
human CM (  3, 10, 32, 33  ). Parasite products such as   Pf  GPI 
have been shown to induce infl  ammatory mediators in a TLR2-
dependant manner (  31  –  33  ). In this study, we show that C5a 
enhances   Pf  GPI-induced infl  ammatory responses (  Fig. 6  ), as 
it does for LPS (  40  –  42  ), and may contribute to the marked 
infl  ammatory response and endothelial cell activation that 
are central to the pathophysiology of CM (  3, 32, 43, 44  ). 
In addition, C5aRs are constitutively expressed by CNS neu-
rons, suggesting that they may be at risk in settings of CM-
associated infl  ammation and complement activation (  45  ). 
  Several studies have reported that parasite burden does 
not appear to play a pivotal role in the development of CM 
in the PbA model (  8, 9, 32  ). Consistent with these data, we 
observed no signifi  cant diff  erence in parasitemia between CM-
susceptible and -resistant mice, suggesting that C5/C5a does 
not signifi  cantly aff  ect parasite burden (  7  –  9, 32  ). However, 
we observed that highly susceptible 129sv/J mice had signifi  -
cantly higher parasite densities than either susceptible or re-
sistant mice (  Fig. 1 B   and Fig. S1). The inability of this strain 
to control initial parasitemia may predispose 129sv/J mice 
to more severe disease and the rapid development of CM. 
As suggested by Amante et al. (  46  ), these fi  ndings indicate 
that parasite burden may also contribute to the pathogenesis of 
    Figure 3.         Survival and C5a levels in BALB/c, C57BL/6, and A/J 
mice.   Sequence analysis showed that the BALB/c mice used in these 
studies were   C5   suffi  cient and therefore, by our hypothesis, should be 
susceptible to PbA-induced CM. (A) However, BALB/c mice are highly 
resistant to CM despite   C5   suffi  ciency (P   <   0.0001 and     2   = 16.531 using 
a log-rank test). The fi  gure is representative of two independent experi-
ments (  n   = 10 mice/group/experiment). 100% of C57BL/6 mice developed 
CM compared with 0% BALB/c mice. (B) Serum C5a levels of C57BL/6, 
BALB/c, and A/J mice are represented by mean OD at 405 nm (error bars 
show SD). C57BL/6 mice had higher circulating C5a levels, particularly on 
days 1 and 5 compared with A/J (  C5 -defi  cient) mice, whereas BALB/c 
mice only show a C5a peak at day 5 and not early in the course of PbA 
infection (**, P   <   0.0001; *, P   <   0.05; and #, P   <   0.01 using a Mann-Whitney 
U test). The graph represents pooled data from two independent 
experiments (  n   = 5 mice/group/experiment).     
    Figure 2.         The role of   C5   in the development of PbA-induced 
  experimental CM in C3H/HeN mice.   To determine the phenotype and role 
of   C5   in PbA infection in the   C5 -suffi  cient mice strain C3H/HeN, C3H/HeN 
mice, as well as control strains A/J (CM resistant) and C57BL/6 (CM sus-
ceptible), were challenged with PbA. C3H/HeN mice were susceptible to 
the development of CM (100% developed CM) and displayed similar mor-
tality rates as C57BL/6 (  C5 -suffi  cient) mice (C57BL/6 vs. C3H/HeN: P = 
0.2237 and     2   = 1.481 using a log-rank test), but signifi  cantly higher 
rates than A/J (  C5 -defi  cient) mice (A/J vs. C3H/HeN: P = 0.0033 and     2   = 
8.656; and C57BL/6 vs. A/J: P = 0.0017 and     2   = 9.879 using a log-rank 
test). The data are representative of two independent experiments (  n   =  10 
mice/group/experiment).   JEM VOL. 205, May 12, 2008 
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value in patients who are at risk of CM but have not yet de-
veloped the syndrome. To defi  ne the role of C5a as a puta-
tive mediator of human CM and determine whether elevated 
C5a levels will be a useful biomarker will require additional 
study in prospective clinical trials. 
  Interventions that prevent CM would be of potential clini-
cal benefi  t in the management of human   P. falciparum   infection 
(  2  ). In this study, C5a  –  C5aR blockade results in signifi  cant 
protection against CM in infected susceptible mice (  Fig. 7  ). 
Although the precise trigger of complement activation during 
malaria infection requires further investigation, the observa-
tions that C5a is required for the development of experimental 
  Current evidence indicates that a tightly regulated proin-
fl  ammatory response is critical in the control and resolution of 
malaria infection, whereas excessive and sustained infl  amma-
tory responses contribute to immunopathology (  8,10-12, 
53  –  55  ). Similar to infl  ammatory responses to infection, our 
fi  ndings indicate that both the timing and the peak concentra-
tions of C5a are important in determining outcome. We show 
that early induction of C5 activation during the course of 
infection contributes to potentiated infl  ammatory responses and 
predisposes mice to the development of CM (e.g., C57BL/6 
mice). Conversely, BALB/c mice do not display early activa-
tion of C5 but rather a gradual activation that may facilitate 
the regulated responses necessary for the control of acute PbA 
infection while limiting host immunopathology. 
  High levels of circulating C5a in the susceptible mice are 
consistent with studies of severe malaria and experimental ma-
laria challenge models in humans, which reported activation 
of the complement system by both the classical and alterna-
tive pathways during human infection (  56  –  58  ). The observa-
tion that C5a appears very early in the course of experimental 
CM supports its role as a potential early mediator and also 
suggests that it may be a useful biomarker to predict those 
who will go on to develop CM. Because only a small propor-
tion of malaria-infected individuals progress to severe disease, 
a predictive biomarker would be of clinical utility in identify-
ing and more eff  ectively allocating therapeutic resources to 
those at greater risk of adverse outcomes. To be valuable as a 
biomarker would require that C5a levels have a predictive 
    Figure 4.         Congenic mice confi  rm a role for   C5   in susceptibility to 
CM.   To further explore the hypothesis that C5a contributes to the patho-
genesis of CM, we examined the phenotype in recombinant congenic mice 
derived from systematic inbreeding of A/J and C57BL/6 mice that differ in 
their   C5   status. Transfer of the   C5 -suffi  cient allele onto an A/J back-
ground in AcB55 mice accelerated the development of CM and fatal out-
comes, whereas BcA76 mice that carry the A/J   C5   defi  ciency allele had 
reduced incidence of CM and improved survival compared with parental 
C57BL/6 mice. The data are representative of two independent experi-
ments (  n   = 10 mice/group/experiment).   C5 -defi  cient congenic mice sur-
vive signifi  cantly longer than   C5 -suffi  cient congenic mice (P   <   0.05 and 
    2   = 4.038 using a log-rank test).     
    Figure 5.         Role of C5 in pathogenesis of CM in closely related 
B10.D2 mouse strains.   To examine whether the survival difference was 
solely attributable to C5, the congenic B10.D2/nSnJ (  C5 -suffi  cient) and 
B10.D2/oSnJ (  C5 -defi  cient) mice were infected with PbA. (A) B10.D2/oSnJ 
mice are resistant to the development of CM and survive signifi  cantly 
longer than   C5 -suffi  cient mice (75 vs. 0%; P   <   0.0001 and     2   =  12.274 
using a log-rank test). The fi  gure is representative of two independent 
experiments (  n   = 8 mice/group/experiment). 100% of B10.D2/nSnJ mice 
developed CM compared with 25% of B10.D2/oSnJ mice. (B) Levels of 
serum C5a, shown as mean OD at 405 nm, were signifi  cantly increased 
in   C5 -suffi  cient (B10.D2/nSnJ) mice compared with   C5 -defi  cient (B10.D2/
oSnJ) mice at days 1, 3, 5, and 7 after infection (*, P   <   0.0001 using a 
Mann-Whitney U test). The data are representative of two independent 
experiments (  n   = 5 mice/group/experiment). Data are presented as 
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  MATERIALS AND METHODS 
  Mice, parasites, and experimental infections.     Experiments involving 
animals were reviewed and approved by the University of Toronto Animal 
Use Committee and were performed in compliance with current University 
of Toronto animal use guidelines. Mice used in this study were 8  –  16 wk old 
and were maintained under pathogen-free conditions with a 12-h light 
cycle. C57BL/6 and BALB/c mice were purchased from Charles River Labo-
ratories. 129sv/J, C3H/HeN, 129P3/J, DBA/2J, A/J, AKR/J, B10.D2/oSnJ, 
and B10.D2/nSnJ mice were purchased from the Jackson Laboratory. 
  PbA parasites were maintained by passage through naive C57BL/6 
mice, as previously described (  29, 32  ). Experimental infections were initi-
ated by i.p. injection of 5   ×   10  5   PbA-parasitized erythrocytes. The course of 
infection was monitored twice daily for neurological symptoms including 
mono-, hemi-, para-, or tetraplegia, movement disorder, ataxia, hunching, 
convulsions, and coma, to defi  ne CM as previously described (  3  –  9, 26  –  28, 
46, 60  ). Mice were judged to have CM if they displayed these neurological 
criteria within days 6  –  10 after infection and either succumbed to infection 
or were humanely killed as per the requirements of our institutional animal 
use committee. Parasitemias were monitored using thin blood smears stained 
with modifi  ed Giemsa stain (Protocol Hema 3 stain set; Sigma-Aldrich) 
from 3 d after infection onwards. CM was confi  rmed by histological exami-
nation of cerebral pathology. Brain tissue was carefully removed, fi  xed in 
10% neutral-buff  ered formalin, embedded, sectioned (5   μ  M), and stained 
with Giemsa or hematoxylin and eosin. 
    C5   defi  ciency and sequencing of the   C5   gene in BALB/c mice.     All 
  C5  -defi  cient mice used in this study had a bp deletion at positions 62 and 63 
of the   C5   gene, which was fi  xed in several strains during their generation. 
This frame-shift caused a premature stop codon that resulted in these mice 
being unable to produce   C5   mRNA or functional C5 protein. 
  The coding region of the   Hc   (  C5  ) gene (available from GenBank/
EMBL/DDBJ under GeneID no.   15139  ) was completely sequenced from 
BALB/c/Cr genomic DNA. Primers were designed to amplify all coding 
exons and a minimum of 100 bp in each direction of the fl  anking introns us-
ing Primer3 (Table S1, available at http://www.jem.org/cgi/content/full/
jem.20072248/DC1) (  61  ). Targets were PCR amplifi  ed with Taq Platinum 
HiFi (Invitrogen) using 50 ng DNA per reaction in a GeneAmp PCR 
CM and that blockade of C5a  –  C5aR activity early in the 
course of PbA infection improves outcome identify C5a –  C5aR 
as a potential target for intervention in human severe malaria 
and CM. Additional studies are required to investigate the po-
tential role of C5a in human infection, including CM induced 
by   P. falciparum   malaria. If C5a is subsequently shown to be an 
important mediator in CM in humans, then the availability of 
inhibitors of C5a  –  C5aR, including receptor antagonists and an 
FDA-approved humanized monoclonal antibody against C5, 
might permit direct testing of the hypothesis that C5a  –  C5aR 
blockade will improve clinical outcome (  59  ). In summary, these 
data provide direct evidence for a role for C5a in the develop-
ment of CM in the PbA model, and suggest a potential role for 
excessive complement activation and C5a generation in partic-
ular, in the pathophysiology of human CM. 
    Figure 7.         Blockade of C5a  –  C5aR protects susceptible mice from 
the development of CM.   To identify whether CM outcome in C5-suffi  cient 
mice could be modulated, C5aR was blocked using antibody treatment of 
PbA-infected mice. B10.D2/nSnJ (  C5 -suffi  cient) mice that received anti-
C5aR serum (  n   = 8) were signifi  cantly protected from developing CM 
compared with controls receiving nonimmune serum (  n   = 7; P = 0.0022 
and     2   = 9.414 using a log-rank test). 100% of B10.D2/nSnJ mice treated 
with nonimmune serum developed CM compared with 0% of B10.D2/nSnJ 
mice treated with anti-C5aR serum.     
    Figure 6.         C5a potentiates   Pf  GPI-induced infl  ammatory cytokines, 
and amplifi  ed responses are inhibited by C5aR blockade.   Human 
PBMCs were treated in three groups as follows: (a) no antibody treat-
ment (control); (b) 5   μ  g/ml of mouse anti-C5aR blocking antibody; or 
(c) mouse anti  –  human IgG2a      isotype control. Each group was subse-
quently treated with 50 nM C5a   ±   300 ng/ml HPLC-purifi  ed   Pf GPI  for 
6  –  24 h, and the supernatants were assayed for the production of TNF 
and IL-6. Statistical analysis was performed by two-way analysis of 
variance and is representative of the interaction effect (C5a*  Pf GPI). 
A  Student ’ s   t   test was used to assess whether blockade of C5aR inhibited 
cytokine induction. (A) C5a potentiated   Pf  GPI-induced TNF production 
at 6 h (**, P = 0.0064), and this effect was inhibited by blocking C5aR 
(***, P = 0.0008). (B) C5a potentiated   Pf  GPI-induced IL-6 production at 
24 h (***, P = 0.0001), and this effect was inhibited by C5aR blockade 
(**, P = 0.0013). Data are representative of two independent experiments 
and are presented as means   ±   SEM.     JEM VOL. 205, May 12, 2008 
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either 0.5 ml anti-C5a or anti-C5aR serum i.p. 2 h before parasite challenge, 
and the control groups received 0.5 ml of corresponding nonimmune serum 
(control serum). Mice were challenged with 5   ×   10  5   PbA-parasitized eryth-
rocytes. After 30  –  32 h, mice received a second injection of 0.5 ml anti-C5a, 
anti-C5aR, or control serum. Mice were monitored for 15 d. 
  Statistical analysis.     Survival studies were analyzed using the log-rank test, 
parasitemias were analyzed using the Kruskal-Wallis test with Dunn  ’  s multi-
ple comparison test, and serum C5a levels were analyzed using the Mann-
Whitney U test. Data are presented as means   ±   SD unless otherwise noted. 
All experiments were repeated at least two times. 
  Online supplemental material.     Fig. S1 shows the parasitemia data over 
the course of infection for various strains infected with PbA. Table S1 shows 
the primers used to sequence the C5 gene from BALB/c mice. Primers 
were designed using Primer3 (  61  ) to amplify all exons and a minimum of 
100 bp in each direction of the fl  anking introns. Table S2 shows the prim-
ers used for quantitative real-time RT-PCR detection of C5 mRNA lev-
els in mice. Online supplemental material is available at http://www.jem
.org/cgi/content/full/jem.20072248/DC1. 
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